Edit

Envisagenics

https://www.envisagenics.com/

Last activity: 05.06.2024

Active

Categories: AnalyticsArtificial IntelligenceBioTechDataDevelopmentDrugLearnMedtechPlatformTechnology

Envisagenics is the latest bioinformatics spinout of Cold Spring Harbor Laboratory aiming to develop a predictive analytics platform for BioPharma

Likes

507

Followers

1.13K

Website visits

5.8K /mo.

Mentions

Persons

Location: United States, New York

Employees: 11-50

Total raised: $3.85M

Founded date: 2014

Founders name: Maria Luisa Pineda, PhD.; Martin Akerman

Twitter

Facebook

Youtube

Investors 7

Date	Name	Website
-	Dolby Fami...	dolbyventu...
-	Madrona Ve...	madrona.co...
-	Dynamk Cap...	dynamk.vc
-	Breakout L...	breakoutla...
-	M12	m12.vc
-	Red Cell P...	redcellpar...
-	Hawktail M...	hawktail.c...

Funding Rounds 2

Date	Series	Amount	Investors
22.05.2018	Grant	$1.5M	-
04.12.2017	Seed	$2.35M	-

Persons 3

Date	First Name	Last Name	Title	LinkedIn	Twitter	Email	Location
-	Anson	Abraham	Data Czar	linkedin.c...	-	a******m@e...	-
-	Maria Luis...	Pineda, Ph...	CEO, Cofou...	linkedin.c...	-	m******a@e...	-
-	Martin	Akerman	CTO, Cofou...	linkedin.c...	-	m******n@e...	-

Mentions in press and media 27

Date	Title	Description
05.06.2024	Envisagenics Raises Series B Funding	Envisagenics, a NYC-based AI-driven revenue generating biotechnology company focused on discovery and development of novel RNA splicing therapeutics, raised a Series B fundraising round of undisclosed amount. Backers included existing inves...
13.12.2022	Envisagenics, Cancer Research Horizons, and Queen Mary University of London Announce Strategic Collaboration Agreement	Envisagenics, an AI-driven biotechnology company that delivers therapies for RNA splicing diseases, announced a research collaboration agreement with Cancer Research Horizons, Cancer Research UK’s innovation engine, and Queen Mary Universit...
29.11.2022	Portfolio Company Envisagenics enters into Multi-Year Collaboration with BMS	Today portfolio company, Envisagenics, announce a multi-year research collaboration agreement with Bristol-Myers Squibb. Together, they will leverage Envisagenics’ SpliceCore, a cloud-based AI Platform that identifies alternative splicing t...
29.11.2022	Envisagenics Announces Research Collaboration with Bristol Myers Squibb	Envisagenics, an Artificial Intelligence (AI)-driven biotechnology company that delivers therapies for RNA splicing diseases, announced a research collaboration agreement with Bristol Myers Squibb. The multi-year collaboration will leverage...
02.03.2022	Alliance for Artificial Intelligence in Healthcare Elects New Board Leadership for 2022	“AI will continue to have a demonstrable impact on human health. Having spent the last three years ideating with my fellow charter members to establish AAIH, I’m honored to take the reins and thrilled I get to engage with an incredible team...
01.10.2021	Envisagenics Raises Series A Financing	Envisagenics, a NYC-based Artificial Intelligence-driven biotechnology company focused on the discovery and development of novel RNA splicing therapeutics, secured a Series A financing of undisclosed amount. The round was led by Red Cell Pa...
29.09.2021	Envisagenics Raises Series A Financing to Scale Its AI-powered RNA Splicing Drug Discovery Platform	NEW YORK, Sept. 29, 2021 /PRNewswire/ -- Envisagenics, an Artificial Intelligence-driven biotechnology company focused on the discovery and development of novel RNA splicing therapeutics, secured Series A financing to scale its drug discove...
29.09.2021	Envisagenics : Raises Series A Financing to Scale Its AI-powered RNA Splicing Drug Discovery Platform	NEW YORK, Sept. 29, 2021 /PRNewswire/ -- Envisagenics, an Artificial Intelligence-driven biotechnology company focused on the discovery and development of novel RNA splicing therapeutics, secured Series A financing to scale its drug discove...
02.06.2018	SV Angel goes ‘back to basics’ as partners exit	Although SV Angel Partners Brian Pokorny, Kevin Carter and Robert Pollak will stay on as advisers to SV Angel, Ron and his son Topher Conway will continue to co-manage the existing SV Angel funds. They will also go “back to basics” and cont...
22.05.2018	Biotech startup Envisagenics receives $1.5 million grant from NIH to accelerate RNA therapeutics discovery	Do you know that cancer and genetic diseases affect more than 30 million people? Here are some facts about these diseases: 15% of all disease-causing mutations are predicted to disrupt RNA splicing. 370 known genetic disorders in publicatio...
01.05.2018	Microsoft’s global Innovate.AI competition unearths AI trends	Innovate.AI, a Microsoft-led global competition for artificial intelligence (AI) startups, has officially come to a close — with three regional winners emerging from around the world. A fourth company has claimed the “AI for Good” prize. Mi...
01.05.2018	M12 Announces Four Winners of Innovate.AI	At Collision Conference, M12, Microsoft Corp.’s venture fund (formerly known as Microsoft Ventures), Madrona Venture Group, Notion Capital and Vertex Ventures announced the four winners of its global startup competition, Innovate.AI. The wi...
01.05.2018	Microsoft’s global Innovate.AI competition unearths AI trends	We are excited to bring Transform 2022 back in-person July 19 and virtually July 20 - 28. Join AI and data leaders for insightful talks and exciting networking opportunities. Register today! Innovate.AI, a Microsoft-led global competition f...
01.05.2018	Microsoft Ventures rebrands as M12, together with its VC partners, awarded $3.5 million to most innovative companies harnessing the power of artificial intelligence	Microsoft has decided to change the name of its venture capital (VC) fund from Microsoft Ventures to M12 to highlight its ongoing commitment to the innovators and entrepreneurs its support. The change came two years after its official launc...
18.03.2018	Венчурный фонд Microsoft и промежуточные итоги AI/ML конкурса	У компании Microsoft есть своё венчурное подразделение – корпоративный венчурный фонд Microsoft Ventures (MV). MV инвестирует в стартапы на раундах от A до D. Ключевые локации – Кремниевая долина, Нью Йорк, Сиэтл, Лондон и Тель-Авив. Фокус ...
04.12.2017	AI and RNA splicing: Is Envisagenics’ $2.35M seed round a sign of what’s to come?	That last feature was a coincidence, said to Co-founder and CEO Maria Luisa Pineda. “We actually didn’t realize that until we started putting the press release together and counting [the female VCs],” Pineda said in a phone interview. Envis...
30.11.2017	Envisagenics Closes $2.35M Seed Round	-
30.11.2017	Envisagenics Closes $2.35M Seed Round	Envisagenics, Inc., a biotechnology company that applies Artificial Intelligence to the genetic sequence of patients to discover new therapies, announced today that is has raised $2.35M in its seed round. The investors include Third Kind Ve...
29.11.2017	Term Sheet — Wednesday, November 29	5 Qs WITH A DEALMAKER Good morning, Term Sheet readers. Paid Content Securing the enterprise without boundaries From ExtraHop “I went to MIT and fell in love with the idea of helping my peers build businesses,” Gupta says. “This was back in...
28.11.2017	Envisagenics Raises $2.25m in Seed Funding	Envisagenics, Inc., a New York, NY-based early drug discovery company, raised $2.25m in seed funding. The round was led by Dynamk Capital with participation from other investors including Third Kind Venture Capital (3KVC), Cosine, LLC (NYC ...
28.11.2017	Envisagenics Raises $2.25 Seed Round	NEW YORK, NY, Envisagenics, which is focused on discovering RNA therapeutics, has raised $2.25 million in seed funding. >> Click here for more funding data on Envisagenics >> To export Envisagenics funding data to PDF and Ex...
13.04.2017	Breakout Labs backs antibacterials, genomics and biosensor tattoos	From California to Boston to NYC, four more startups have been accepted into the [Peter] Thiel Foundation’s Breakout Labs, a philanthropic incubator for seed-stage companies. Founded in 2012, Breakout Labs has now invested in some 34 compan...
13.04.2017	Term Sheet — Thursday, April 13	FEELING TOPPY Today Yext will go public on NYSE under the symbol YEXT. It’s a small IPO, valuing the company at around $940 million. Last night the company boosted pricing by $1 a share to $11 a share, for a total raise of $115.5 million. P...
-	AI and RNA splicing: Is Envisagenics’ $2.35M seed round a sign of what’s to come?	Can a three-year-old biotech spin-out from Cold Spring Harbor Laboratory offer a glimpse into the future? Envisagenics certainly hits on some major trends in its technology, location, and inaugural financing round. The startup is in the bus...
-	SV Angel goes ‘back to basics’ as partners exit	SV Angel, a seed stage investment group that has backed several healthcare companies, is scaling down — it won’t raise any more new funds, it will reduce investment sizes and has parted ways with its partners. The seed fund had made investm...
-	Envisagenics	“RNA Therapeutics Development”
-	Breakout Labs backs antibacterials, genomics and biosensor tattoos	From California to Boston to NYC, four more startups have been accepted into the [Peter] Thiel Foundation’s Breakout Labs, a philanthropic incubator for seed-stage companies. Founded in 2012, Breakout Labs has now invested in some 34 compan...

Envisagenics

Investors 7

Funding Rounds 2

Persons 3

Mentions in press and media 27

Reviews 0